Lumasiran

• CAT Number: I045371
• CAS Number: 1834610-13-7
• Molecular Weight: 16339.00 (AS: 7631.0 +SS: 8708.0)
• Purity: 95%
• Target: HAO1 mRNA
• Target Protein: Q9UJM8
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.

Lumasiran（Cat No.:I045371）is an RNA interference (RNAi) therapeutic used to treat primary hyperoxaluria type 1 (PH1), a rare genetic disorder that leads to excessive oxalate production, causing kidney stones and kidney damage. Lumasiran targets and silences the HAO1 gene, reducing the production of glycolate oxidase, an enzyme involved in oxalate formation. By decreasing oxalate levels, Lumasiran helps prevent kidney complications and improves patient outcomes. Administered via subcutaneous injection, it offers a targeted treatment option that addresses the underlying cause of PH1, significantly reducing the risk of kidney failure and other complications.

Reference

[1]. Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282.
[Content Brief]

[2]. Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021;384(13):1216-1226.
[Content Brief]